中国中西医结合杂志2025，Vol.45Issue(5)：538-546,9.DOI:10.7661/j.cjim.20250414.140
芪参益气滴丸干预非ST段抬高型急性冠脉综合征患者经皮冠状动脉介入后前瞻性队列研究
Qishen Yiqi Dripping Pills in the Treatment of Patients with Non-ST-segment Elevation Acute Coronary Syndrome undergoing Percutaneous Coronary Intervention:A Prospective Cohort Study
摘要
Abstract
Objective To evaluate the effectiveness of Qishen Yiqi dripping pill(QYDP)in patients with non-ST-segment elevation acute coronary syndrome(NSTE-ACS)after percutaneous coronary intervention(PCI).Methods A multicenter,prospective cohort study was conducted,enrolling 807 patients with NSTE-ACS who underwent PCI between 2012 and 2015.Patients were assigned to two groups based on the usage of QYDP:408 patients received QYDP in addition to conventional medicine(CM,QYDP group),and 399 patients received conventional medicine alone(CM group),the treatment course was 12 months.The incidence of major adverse cardiovascular and cerebrovascular events(MACCE)over 3 years was compared using a Cox proportional hazards model.Propensity score matching(PSM)was used to adjust for confounding factors.Restricted mean survival time(RMST)analysis was performed to compare event-free survival times between the groups.Blood stasis syndrome scores were assessed at 1,3,6,and 12 months after enrollment.Results A total of 26 patients were lost to follow-up in each group,resulting in 382 patients in the QYDP group and 373 patients in the CM group for final analysis.Cox regression analysis showed that the incidence of MACCE was significantly lower in the QYDP group compared with the CM group(HR:0.64,95％CI:0.44～0.93,P=0.019).After PSM,the QYDP group continued to show a significantly lower 3-year incidence of MACCE(HR:0.49,95％CI:0.31～0.75,P=0.001).RMST analysis indicated that event-free survival time was significantly prolonged in the QYDP group at the day of 365(14.56 days,95％CI:4.93～24.18,P=0.003)and the day of 730(35.56 days,95％CI:7.60～63.52,P=0.013)compared to the CM group.Blood stasis syndrome scores were significantly lower in the QYDP group at 6 and 12 months after enrollment(P=0.034,P＜0.001).Conclusion The combination of QYDP with CM significantly reduced the risk of MACCE and the level of blood stasis syndrome score in patients with NSTE-ACS after PCI.(ChiCTR No.ChiCTR-OOC-14005552)关键词
芪参益气滴丸/经皮冠状动脉介入治疗/非ST段抬高型急性冠脉综合征/主要不良心脑血管事件/中成药/中西医结合/队列研究Key words
Qishen Yiqi Dripping Pills/percutaneous coronary intervention/non-ST-segment elevation acute coronary syndrome/major adverse coronary and cerebrovascular event/Chinese patent medicine/integrative medicine/cohort study引用本文复制引用
于燕乔,白瑞娜,杨芙蓉,崔卓睿,杨严凯,蔡雅杰,盛松,杨巧宁,李立志,史大卓..芪参益气滴丸干预非ST段抬高型急性冠脉综合征患者经皮冠状动脉介入后前瞻性队列研究[J].中国中西医结合杂志,2025,45(5):538-546,9.基金项目
国家中医药行业科研专项(No.201007001) （No.201007001）
中国中医科学院西苑医院名老中医经验传承研究专项(No.XYZX001-01) （No.XYZX001-01）
中央级公益性科研院所基本科研业务费专项资金(No.ZZ13-YQ-005) （No.ZZ13-YQ-005）
